{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:44:06Z","timestamp":1771267446468,"version":"3.50.1"},"reference-count":33,"publisher":"Georg Thieme Verlag KG","issue":"05","funder":[{"name":"National Major Scientific and Technological Special Project for \u201cSignificant New Drugs Development\u201d during the Thirteenth Five-year Plan Period","award":["2017ZX09304017"],"award-info":[{"award-number":["2017ZX09304017"]}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"crossref","award":["ZYLX201805"],"award-info":[{"award-number":["ZYLX201805"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Objective\u2003This article compares the clinical outcomes of clopidogrel and ticagrelor in patients with acute coronary syndrome (ACS) without cytochrome P450 (CYP)2C19 loss-of-function (LOF) alleles and investigates whether clopidogrel could be an alternative P2Y12 inhibitor without increasing the risk of ischemic events.<\/jats:p><jats:p>\n          Methods\u2003Patients were divided into the clopidogrel-treated group and the ticagrelor-treated group. Inverse probability of treatment weighting (IPTW) calculated by propensity scores was used to adjust confounding covariates. The primary outcome was major adverse cardiovascular or cerebrovascular events (MACCEs) within 12 months. The secondary outcomes were MACCEs plus unstable angina, and clinically significant bleeding events.<\/jats:p><jats:p>\n          Results\u2003Finally, 2,199 patients were included. Of them, 1,606 were treated with clopidogrel, and 593 were treated with ticagrelor. The mean age of the original cohort was 59.92\u2009\u00b1\u20099.81 years. During the 12-month follow-up period, MACCEs occurred in 89 patients (4.0%). No significant differences were observed in MACCEs (IPTW-adjusted hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.65\u20131.18), MACCEs plus unstable angina (IPTW-adjusted HR, 1.20; 95% CI, 0.91\u20131.59), or clinically significant bleeding events (IPTW-adjusted HR, 0.81; 95% CI, 0.53\u20131.23) between the clopidogrel- and ticagrelor-treated groups.<\/jats:p><jats:p>\n          Conclusion\u2003In patients with ACS without CYP2C19 LOF alleles, clopidogrel was not associated with a higher risk of MACCEs when compared with ticagrelor. The main findings of this study support use of clopidogrel in CYP2C19 LOF noncarriers as an alternative P2Y12 inhibitor, which may reduce medical expenses and adverse reactions caused by more potent P2Y12 inhibitors in these patients.<\/jats:p>","DOI":"10.1055\/s-0041-1735193","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T23:03:12Z","timestamp":1629846192000},"page":"842-852","source":"Crossref","is-referenced-by-count":4,"title":["Clopidogrel versus Ticagrelor in CYP2C19 Loss-of-Function Allele Noncarriers: A Real-World Study in China"],"prefix":"10.1055","volume":"122","author":[{"given":"Yunnan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"},{"name":"School of Pharmaceutical Sciences, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"},{"name":"School of Pharmaceutical Sciences, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baidi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"},{"name":"School of Pharmaceutical Sciences, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialun","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"},{"name":"School of Pharmaceutical Sciences, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"},{"name":"School of Pharmaceutical Sciences, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"},{"name":"School of Pharmaceutical Sciences, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxing","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"},{"name":"School of Pharmaceutical Sciences, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"issue":"23","key":"ref1","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"G N Levine","year":"2011","journal-title":"Circulation"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"134","author":"G N Levine","year":"2016","journal-title":"Circulation"},{"issue":"20","key":"ref3","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"S D Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"08","key":"ref5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"N L Pereira","year":"2020","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial","volume":"379","author":"J D Roberts","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nrcardio.2009.154","article-title":"Cardiovascular pharmacogenomics and individualized drug therapy","volume":"6","author":"N L Pereira","year":"2009","journal-title":"Nat Rev Cardiol"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"e007811","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","article-title":"Clopidogrel pharmacogenetics","volume":"12","author":"N L Pereira","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10557-020-06956-4","article-title":"Ticagrelor versus clopidogrel in patients with two CYP2C19 loss-of-function alleles undergoing percutaneous coronary intervention","volume":"34","author":"Z Xi","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"L Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"e009434","DOI":"10.1161\/CIRCINTERVENTIONS.120.009434","article-title":"Clopidogrel versus ticagrelor or prasugrel after primary percutaneous coronary intervention according to CYP2C19 genotype: A POPular Genetics subanalysis","volume":"14","author":"D MF Claassens","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"582929","DOI":"10.3389\/fphar.2020.582929","article-title":"Impact of implementing CYP2C19 genotype-guided antiplatelet therapy on P2Y12 inhibitor selection and clinical outcomes in acute coronary syndrome patients after percutaneous coronary intervention: a real-world study in China","volume":"11","author":"Y Zhang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"S A Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"J Y Hahn","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.111.060871","article-title":"Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention","volume":"125","author":"G Ndrepepa","year":"2012","journal-title":"Circulation"},{"issue":"24","key":"ref16","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"E A Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","article-title":"Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"L H Cavallari","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"28","key":"ref18","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"P C Austin","year":"2015","journal-title":"Stat Med"},{"issue":"16","key":"ref19","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"J L Mega","year":"2010","journal-title":"JAMA"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2010.05.013","article-title":"ACCF\/AHA clopidogrel clinical alert: approaches to the FDA \u201cboxed warning\u201d: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons","volume":"56","author":"D R Holmes Jr","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"39","author":"B Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"e006132","DOI":"10.1161\/CIRCINTERVENTIONS.117.006132","article-title":"Frequency, reasons, and impact of premature ticagrelor discontinuation in patients undergoing coronary revascularization in routine clinical practice: results from the Bern Percutaneous Coronary Intervention Registry","volume":"11","author":"T Zanchin","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"issue":"13","key":"ref23","first-page":"1274","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"373","author":"M Flather","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"ref24","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"D MF Claassens","year":"2019","journal-title":"N Engl J Med"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"e002069","DOI":"10.1161\/CIRCGEN.117.002069","article-title":"Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"C R Lee","year":"2018","journal-title":"Circ Genom Precis Med"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1080\/03007995.2020.1825364","article-title":"Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention","volume":"36","author":"J Li","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11886-014-0485-4","article-title":"\u201cEast Asian Paradox\u201d: challenge for the current antiplatelet strategy of \u201cone-guideline-fits-all races\u201d in acute coronary syndrome","volume":"16","author":"Y H Jeong","year":"2014","journal-title":"Curr Cardiol Rep"},{"issue":"07","key":"ref28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcin.2021.01.024","article-title":"Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis","volume":"14","author":"N L Pereira","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"G N Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12967-018-1469-8","article-title":"Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention","volume":"16","author":"L H Cavallari","year":"2018","journal-title":"J Transl Med"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"D J Angiolillo","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/0300060516677190","article-title":"Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome","volume":"45","author":"C C Tam","year":"2017","journal-title":"J Int Med Res"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40256-019-00337-5","article-title":"Prasugrel vs. ticagrelor for acute coronary syndrome patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"19","author":"M S Khan","year":"2019","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1735193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T23:42:02Z","timestamp":1655250122000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1735193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":33,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2022,6,14]]},"published-print":{"date-parts":[[2022,5]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1735193","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]}}}